Loading clinical trials...
Loading clinical trials...
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevent...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Allergan
NCT03237845 · Migraine, With or Without Aura
NCT03461757 · Migraine, With or Without Aura
NCT02873221 · Migraine, With or Without Aura
NCT02867709 · Migraine, With or Without Aura
Achieve Clinical Research
Birmingham, Alabama
Radiant Research, Inc.
Chandler, Arizona
The Research Center of Southern California, LLC
Carlsbad, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions